Verastem Oncology appoints Michael P. Bailey as CEO, succeeding retiring Daniel Paterson
Verastem Oncology announced that Michael P. Bailey will become President and Chief Executive Officer on January 1 2027, taking over from Daniel Paterson who will retire and stay on the board as an advisor. Bailey brings more than 30 years of biopharma experience, including over 25 years in oncology. Paterson led the FDA approval of the company’s AVMAPKI FAKZYNJA CO‑PACK in 2025 and advanced the KRAS‑G12D inhibitor VS‑7375 into Phase 2 trials.
Why it matters
The leadership change sparked a pre‑market rally of almost 20%, with the stock closing at $7.45 on Tuesday. Investors may view the new CEO’s extensive oncology background as a catalyst for accelerating pipeline development and commercial growth.
Key facts
- 1Michael P. Bailey was appointed President and CEO effective January 1 2027. stocktitan.net
- 2Daniel Paterson will retire as CEO and remain a board director and advisor. stocktitan.net
- 3Bailey has more than 30 years of biopharmaceutical experience, including over 25 years in oncology. stocktitan.net
- 4Paterson led the FDA approval of AVMAPKI FAKZYNJA CO‑PACK on May 8 2025. investing.com
- 5Verastem shares rose nearly 20% in pre‑market trading and closed at $7.45 on Tuesday. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.